Scopus Biopharma

Scopus Biopharma R&D per Employee

The R&D Spending per Employee of Scopus Biopharma (SCPS) as of Nov 19, 2026 is 206,288.08 USD. In the previous year, R&D Spending per Employee was 1.16 M USD — a change of -82.15% (lower).

R&D per Employee

206,288.08USD

YoY

-82.15%

Last updated:

R&D Spending per Employee of Scopus Biopharma is 2022 206,288.08 USD. R&D Spending per Employee of Scopus Biopharma was 2021 1.16 M USD. It decreases by -82.15% lower compared to the previous year.

The Scopus Biopharma R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
21,349.15 USD
Jan 1, 2019
35,623.92 USD
Jan 1, 2020
571,060.46 USD
Jan 1, 2021
1.16 M USD
Jan 1, 2022
206,288.08 USD
The Scopus Biopharma R&D per Employee history
YEARR&D per EmployeeYoY
206,288.08USD-82.15%
1.16 MUSD+102.37%
571,060.46USD+1,503.03%
35,623.92USD+66.86%
21,349.15USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scopus Biopharma stock

R&D Spending per Employee of Scopus Biopharma is 206,288.08 USD in 2022.

R&D Spending per Employee of Scopus Biopharma changed from 1.16 M USD to 206,288.08 USD, representing a -82.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Scopus Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Scopus Biopharma

All Key Metrics — Scopus Biopharma